Home Preclinical development

Preclinical development

Merck & Co/MSD and Daiichi Sankyo to Jointly Development and Commercialization Three DXd ADCs

ADC Review | Editorial Team

Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors Supports Advancement to Phase 2 Clinical Studies

BVX001 is Well-tolerated in Preclinical Study – Demonstrating a Favorable Safety Profile Compared with Gemtuzumab Ozogamicin

Recent Advances in Antibody-drug Conjugates Produced Using Chemical Conjugation Technology

BYON4228 Enhances Anti-tumor Immunity In Vitro

REGN3124-PBD a Novel EGFRvIII-selective ADC Shows Promise Against Glioblastoma Multiforme Patient-derived Xenografts

By

ADC Review | Editorial Team

-

Glioblastoma Multiforme (GBM) is a highly aggressive primary malignant brain tumor with few specific molecular targets and poor therapeutic...

Preclinical Study Supports Continued Evaluation of CD25-targeted ADC in Selected Advanced Solid Tumors

By

ADC Review | Editorial Team

-

Preclinical data for camidanlumab tesirine (formerly ADCT-301; ADC Therapeutics), published in the Journal for ImmunoTherapy of Cancer, the online...